Supplement promises bowel relief
This article was originally published in The Tan Sheet
Executive SummaryA study published in the July issue of the American Journal of Gastroenterology finds Bifidobacterium infantis 35624, trademarked under the name Bifantis, may help relieve symptoms of irritable bowel syndrome in women. The randomized, double-blind, placebo-controlled study targeted 362 women ages 18 to 65 diagnosed with IBS. Subjects received either placebo or freeze-dried, encapsulated Bifantis once daily for four weeks. On a daily basis, patients recorded incidents of abdominal pain/discomfort and bloating distensions, incomplete evacuation, straining at stool, urgency of bowel movement, passage of gas and mucous, and bowel movement satisfaction. Bifantis provided superior results over placebo by more than 20% at the end of four weeks. No significant adverse events were recorded. Used as an active ingredient in Align supplements, Bifantis is a calorie/lactose-free "beneficial" bacteria that claims to assist the body's natural defenses and balance other bacteria. It is similar to active cultures found in some yogurts or fermented milks. Align supplements are $29.99 per jar of 28-day supply...
You may also be interested in...
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
The US agency is engaged with an ethylene oxide (EtO) sterilizer in Illinois that has temporarily closed to determine if there are any potential risks to the medical device supply chain. While the plant shut down about a month ago, regulators have only recently been made aware of the decision, which resulted from a law passed last year by the state legislature.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.